Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data Analysis
Standard
Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data Analysis. / Hempel, Louisa; de Oliveira, Julia Veloso; Gaumann, Andreas; Milani, Valeria; Schweneker, Katrin; Schenck, Kristina; Fleischmann, Bastian; Philipp, Patrick; Mederle, Stefanie; Garg, Arun; Piehler, Armin; Gandorfer, Beate; Schick, Cordula; Kleespies, Axel; Sellmann, Ludger; Bartels, Marius; Goetze, Thorsten Oliver; Stein, Alexander; Goekkurt, Eray; Pfitzner, Lucia; Robert, Sebastian; Hempel, Dirk.
In: CANCERS, Vol. 13, No. 17, 4453, 03.09.2021.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data Analysis
AU - Hempel, Louisa
AU - de Oliveira, Julia Veloso
AU - Gaumann, Andreas
AU - Milani, Valeria
AU - Schweneker, Katrin
AU - Schenck, Kristina
AU - Fleischmann, Bastian
AU - Philipp, Patrick
AU - Mederle, Stefanie
AU - Garg, Arun
AU - Piehler, Armin
AU - Gandorfer, Beate
AU - Schick, Cordula
AU - Kleespies, Axel
AU - Sellmann, Ludger
AU - Bartels, Marius
AU - Goetze, Thorsten Oliver
AU - Stein, Alexander
AU - Goekkurt, Eray
AU - Pfitzner, Lucia
AU - Robert, Sebastian
AU - Hempel, Dirk
PY - 2021/9/3
Y1 - 2021/9/3
N2 - After several years of negative phase III trials in gastric and esophageal cancer, a significant breakthrough in the treatment of metastatic adenocarcinomas of the gastroesophageal junction (GEJ) and stomach (GC) is now becoming evident with the emerging of precision oncology and implementation of molecular targets in tumor treatment. In addition, new generation studies such as umbrella and basket trials are focused on these molecular targets, which makes an early molecular diagnosis based on IHC/ISH and NGS necessary. The required companion diagnostics of Her2neu overamplification or PD-L1 expression is based on immunohistochemistry (IHC) or additionally in situ hybridization (ISH) in case of an IHC Her2neu score of 2+. However, there are investigator-dependent differences in the assessment of Her2neu amplification and different PD-L1 scoring systems obtained by IHC/ISH. The use of high-throughput technologies such as next-generation sequencing (NGS) holds the potential to standardize the analysis and thus make them more comparable. In the presented study, real-world multigene sequencing data of 72 Caucasian patients diagnosed with metastatic adenocarcinomas of GEJ and stomach were analyzed. In the clinical companion diagnostics, we found ESCAT level I molecular targets in one-third of our patients, which directly determined the therapy. In addition, we found potential targets in 14/72 patients (19.4%) who potentially qualify for precision therapies in corresponding molecular studies. The study highlights the importance of comprehensive molecular profiling for precision treatment of GEJ/GC and indicates that a biomarker evaluation should be performed for all patients with metastatic adenocarcinomas before the initiation of first-line treatment and during second-line or subsequent treatment.
AB - After several years of negative phase III trials in gastric and esophageal cancer, a significant breakthrough in the treatment of metastatic adenocarcinomas of the gastroesophageal junction (GEJ) and stomach (GC) is now becoming evident with the emerging of precision oncology and implementation of molecular targets in tumor treatment. In addition, new generation studies such as umbrella and basket trials are focused on these molecular targets, which makes an early molecular diagnosis based on IHC/ISH and NGS necessary. The required companion diagnostics of Her2neu overamplification or PD-L1 expression is based on immunohistochemistry (IHC) or additionally in situ hybridization (ISH) in case of an IHC Her2neu score of 2+. However, there are investigator-dependent differences in the assessment of Her2neu amplification and different PD-L1 scoring systems obtained by IHC/ISH. The use of high-throughput technologies such as next-generation sequencing (NGS) holds the potential to standardize the analysis and thus make them more comparable. In the presented study, real-world multigene sequencing data of 72 Caucasian patients diagnosed with metastatic adenocarcinomas of GEJ and stomach were analyzed. In the clinical companion diagnostics, we found ESCAT level I molecular targets in one-third of our patients, which directly determined the therapy. In addition, we found potential targets in 14/72 patients (19.4%) who potentially qualify for precision therapies in corresponding molecular studies. The study highlights the importance of comprehensive molecular profiling for precision treatment of GEJ/GC and indicates that a biomarker evaluation should be performed for all patients with metastatic adenocarcinomas before the initiation of first-line treatment and during second-line or subsequent treatment.
U2 - 10.3390/cancers13174453
DO - 10.3390/cancers13174453
M3 - SCORING: Journal article
C2 - 34503263
VL - 13
JO - CANCERS
JF - CANCERS
SN - 2072-6694
IS - 17
M1 - 4453
ER -